Ligand Pharmaceuticals (FRA:LGDN) Cyclically Adjusted FCF per Share: €3.48 (As of Mar. 2026)


FRA:LGDN Ligand Pharmaceuticals Inc FRA:LGDN
78 GF Score
Price €270.00
GF Value €151.93
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ligand Pharmaceuticals Cyclically Adjusted FCF per Share?

Ligand Pharmaceuticals FRA:LGDN -0.74% 78 Cyclically Adjusted FCF per Share is €3.48 as of Mar. 2026. GuruFocus rates FRA:LGDN with a GF Score™ of 78/100 and a GF Value™ of €151.93 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Ligand Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was €2.108. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €3.48 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ligand Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was 13.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 15.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Ligand Pharmaceuticals was 87.30% per year. The lowest was -2.50% per year. And the median was 14.30% per year.

As of today (2026-07-12), Ligand Pharmaceuticals's current stock price is €270.00. Ligand Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €3.48. Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 77.59.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Ligand Pharmaceuticals was 1014.60. The lowest was 13.58. And the median was 39.55.


Ligand Pharmaceuticals  (FRA:LGDN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=270.00/3.48
=77.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Ligand Pharmaceuticals was 1014.60. The lowest was 13.58. And the median was 39.55.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Ligand Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Ligand Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Ligand Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Ligand Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.28 3.14 3.01 3.64 3.31

Ligand Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.39 3.12 3.02 3.31 3.48

FRA:LGDN vs DFTX, CGON, XENE: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


FRA:LGDN
78GF Score
Ligand Pharmaceuticals Inc FRA:LGDN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ligand Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ligand Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.108/330.2130*330.2130
=2.108

Current CPI (Mar. 2026) = 330.2130.

Ligand Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.354 241.018 -0.485
201609 0.633 241.428 0.866
201612 1.166 241.432 1.595
201703 0.781 243.801 1.058
201706 0.398 244.955 0.537
201709 0.985 246.819 1.318
201712 1.096 246.524 1.468
201803 1.987 249.554 2.629
201806 2.580 251.989 3.381
201809 0.965 252.439 1.262
201812 1.246 251.233 1.638
201903 1.882 254.202 2.445
201906 -2.763 256.143 -3.562
201909 -0.300 256.759 -0.386
201912 -0.367 256.974 -0.472
202003 0.926 258.115 1.185
202006 1.297 257.797 1.661
202009 0.673 260.280 0.854
202012 0.024 260.474 0.030
202103 0.358 264.877 0.446
202106 0.918 271.696 1.116
202109 0.905 274.310 1.089
202112 1.293 278.802 1.531
202203 2.544 287.504 2.922
202206 0.293 296.311 0.327
202209 0.896 296.808 0.997
202212 2.923 296.797 3.252
202303 1.639 301.836 1.793
202306 -0.015 305.109 -0.016
202309 0.386 307.789 0.414
202312 -2.214 306.746 -2.383
202403 0.822 312.332 0.869
202406 0.576 314.175 0.605
202409 1.090 315.301 1.142
202412 1.397 315.605 1.462
202503 -1.325 319.799 -1.368
202506 0.678 322.561 0.694
202509 0.193 324.800 0.196
202512 1.870 324.054 1.906
202603 2.108 330.213 2.108

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €3.48 mean?
Ligand Pharmaceuticals (FRA:LGDN) has a Cyclically Adjusted FCF per Share of €3.48 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ligand Pharmaceuticals and its competitors.
Is Ligand Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Ligand Pharmaceuticals' current Cyclically Adjusted FCF per Share is €3.48. Overall, Ligand Pharmaceuticals has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' Cyclically Adjusted FCF per Share compare to DFTX and CGON?
Ligand Pharmaceuticals' Cyclically Adjusted FCF per Share of €3.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current Cyclically Adjusted FCF per Share is €3.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €151.93, compared to a current price of €270.00 — trading 77.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €3.48. Ligand Pharmaceuticals' overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Cyclically Adjusted FCF per Share is €3.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €270.00 is trading 77.7% above its estimated GF Value™ of €151.93. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:LGDN:

  • Cyclically Adjusted FCF per Share: €3.48
  • GF Value™: €151.93 vs. price of €270.00 (77.7% above fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ligand Pharmaceuticals Business Description

Other Exchanges LGND:USA
Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
78GF Score

Get the complete analysis for FRA:LGDN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€270.00
Price
€151.93
GF Value